Scientific publication by Targetex:

Szilágyi K, Flachner B, Hajdú I, Szaszkó M, Dobi K, Lőrincz Z, Cseh S, Dormán G. (2021)

Rapid Identification of Potential Drug Candidates from Multi-Million Compounds’ Repositories. Combination of 2D Similarity Search with 3D Ligand/Structure Based Methods and In Vitro Screening.

Molecules. 26:E5593 IF: 4,41

Szilágyi K, Hajdú I, Flachner B, Lőrincz Z, Balczer J, Gál P, Závodszky P, Pirli C, Balogh B, Mándity IM, Cseh S, Dormán G. (2019)

Design and Selection of Novel C1s Inhibitors by In Silico and In Vitro Approaches.

Molecules. 24:E3641 IF: 3,267

Hajdú I, Kardos J, Major B, Fabó G, Lőrincz Z, Cseh S, Dormán G. (2018)

Inhibition of the LOX enzyme family members with old and new ligands. Selectivity analysis revisited.

Bioorg Med Chem Lett. 28, 3113-3118. IF: 2,448

Bencsik P, Kupai K, Görbe A, Kenyeres É, Varga ZV, Pálóczi J, Gáspár R, Kovács L, Weber L, Takács F, Hajdú I, Fabó G, Cseh S, Barna L, Csont T, Csonka C, Dormán G, Ferdinandy P. (2018)

Development of Matrix Metalloproteinase-2 Inhibitors for Cardioprotection.

Front Pharmacol, 9,296  IF: 3,845


Szaszkó, M., Hajdú, I., Flachner, B., Dobi, K., Magyar, C., Simon, I., Lőrincz, Z., Kapui, Z., Pázmány, T., Cseh, S., Dormán, G. (2017)

Identification of potential glutaminyl cyclase inhibitors from lead-like libraries by in silico and in vitro fragment-based screening

Molecular Diversity, 21, 175-86. IF:2,229

Dormán G, Nakamura H, Pulsipher A, Prestwich GD. (2016)

The Life of Pi Star: Exploring the Exciting and Forbidden Worlds of the Benzophenone Photophore.

Chem Rev. 116, 15284-15398. IF:47,928

Kelemen ÁA, Kiss R, Ferenczy GG, Kovács L, Flachner B, Lőrincz Z, Keserű GM.

Structure-Based Consensus Scoring Scheme for Selecting Class A Aminergic GPCR Fragments. (2016)

J Chem Inf Model. 56, 412-22. IF: 3,760

Dobi, K., Flachner, B., Pukáncsik, M., Máthé, E., Bognár, M., Szaszkõ, M., Magyar, C., Hajdú, I., Lorincz, Z., Simon, I., Fülöp, F., Cseh, S., Dormán, G. (2015)

Combination of Pharmacophore Matching, 2D Similarity Search, and in Vitro Biological Assays in the Selection of Potential 5-HT6 Antagonists from Large Commercial Repositories

Chemical Biology and Drug Design, 86, 864-80. IF: 2,802

Dobi, K., Hajdú, I., Flachner, B., Fabó, G., Szaszkó, M., Bognár, M., Magyar, C., Simon, I., Szisz, D., Lõrincz, Z., Cseh, S., Dormán, G. (2014)

Combination of 2D/3D ligand-based similarity search in rapid virtual screening from multimillion compound repositories. Selection and biological evaluation of potential PDE4 and PDE5 inhibitors

Molecules, 19, 7008-39. IF: 2,416

Hajdú, I., Flachner, B., Bognár, M., Végh, B.M., Dobi, K., Lorincz, Z., Lázár, J., Cseh, S., Takács, L., Kurucz, I. (2014)

Monoclonal antibody proteomics: Use of antibody mimotope displaying phages and the relevant synthetic peptides for mAb scouting

Immunology Letters, 160, 172-7. IF: 2,512

Flachner, B., Tömöri, T., Hajdú, I., Dobi, K., Lorincz, Z., Cseh, S., Dormán, G. (2014)

Rapid in silico selection of an MCHR1 antagonists’ focused library from multi-million compounds’ repositories: Biological evaluation

Medicinal Chemistry Research, 23, 1234-47. IF: 1,402

Flachner B, Lörincz Z, Carotti A, Nicolotti O, Kuchipudi P, Remez N, Sanz F, Tóvári J, Szabó MJ, Bertók B, Cseh S, Mestres J, Dormán G. (2012)

A chemocentric approach to the identification of cancer targets.

PLoS One. 7, e35582 IF:3,730

Tömöri T, Hajdú I, Barna L, Lőrincz Z, Cseh S and Dormán G (2012)

Combining 2D and 3D in silico methods for rapid selection of potential PDE5 inhibitors from multimillion compounds’ repositories: biological evaluation.

Mol Divers. 16, 59-72 IF: 2,861

Berta J1, Kenessey I, Dobos J, Tovari J, Klepetko W, Jan Ankersmit H, Hegedus B, Renyi-Vamos F, Varga J, Lorincz Z, Paku S, Ostoros G, Rozsas A, Timar J, Dome B. (2010)

Apelin expression in human non-small cell lung cancer: role in angiogenesis and prognosis.

J Thorac Oncol. 5, 1120-9. IF: 4,040

Kenessey I, Keszthelyi M, Krámer Z, Berta J, Adám A, Dobos J, Mildner M, Flachner B, Cseh S, Barna G, Szokol B, Orfi L, Kéri G, Döme B, Klepetko W, Tímár J, Tóvári J. (2010)

Inhibition of c-Met with the specific small molecule tyrosine kinase inhibitor SU11274 decreases growth and metastasis formation of experimental human melanoma.

Curr Cancer Drug Targets 10, 332-42 IF:4,771

Kupai K, Szucs G, Cseh S, Hajdu I, Csonka C, Csont T and Ferdinandy P (2010)

Matrix metalloproteinase activity assays: Importance of zymography.

J Pharmacol Toxicol Methods 61, 205-9

Dormán G, Cseh S, Hajdú I, Barna L, Kónya D, Kupai K, Kovács L and Ferdinandy P (2010)

Matrix metalloproteinase inhibitors: a critical appraisal of design principles and proposed therapeutic utility

Drugs 70, 949-64 IF: 3,738

Vass L1, Kelemen JZ, Fehér LZ, Lorincz Z, Kulin S, Cseh S, Dormán G, Puskás LG. (2009)

Toxicogenomics screening of small molecules using high-density, nanocapillary real-time PCR. 

Int J Mol Med. 23, 65-74 IF: 1,980

Decornez H, Gulyás-Forró A, Papp A, Szabó M, Sármay G, Hajdú I, Cseh S, Dormán G, Kitchen DB. (2009)

Design, selection, and evaluation of a general kinase-focused library.

ChemMedChem. 4,1273-1278. IF:3,150

Book chapter

Dormán, G., Flachner, B., Hajdú, I., András, C.D.

Target identification and polypharmacology of nutraceuticals

(2016) Nutraceuticals: Efficacy, Safety and Toxicity, pp. 263-286.

Publication with Recomgenex affiliation

Molnár L, Keseru GM, Papp A, Lorincz Z, Ambrus G, Darvas F (2006)

A neural network based classification scheme for cytotoxicity predictions:Validation on 30,000 compounds.

Bioorg Med Chem Lett.16, 1037-9. IF: 2,538

Darvas F, Dormán G, Krajcsi P, Puskás LG, Kovári Z, Lörincz Z, Urge L. (2004)

Recent advances in chemical genomics.

Curr Med Chem. 11, 3119-45. IF: 4,382


TargetEx Ltd.

H-2120 Dunakeszi Madách Imre u 31/2.


Sándor Cseh

Chief Executive Officer


Tel.: +361-279-3153

Fax: +361-279-3154

Send a message